Aurinia Pharmaceuticals Inc. Insider Trading

AUPH

⊜ Compare

Last 12 months

Insiders bought $25.1M and sold 546K on the open market.

None of the selling was scheduled in advance under a 10b5-1 plan.

Net open-market

+$24.6M

2 buys · 2 sales

Under a 10b5-1 plan

of the value sold

Insiders who bought / sold

1 / 1

executives and directors

Last open-market buy

Jun 2026

Jun 2, 2026

Get an email when AUPH's executives or directors buy, or make a large sale outside a plan.

Trades · last 2 years

Date	Insider	Trade	Shares	Price	Value	Of their stake	Filing
Sep 10	Stephen P. Robertson Chief Legal Officer	SoldNo plan	11,939	$15.95	190K	2.0%	Form 4
Aug 21	Stephen P. Robertson Chief Legal Officer	SoldNo plan	20,975	$16.97	356K	3.4%	Form 4
May 29 – Jun 2	Kevin Tang Chief Executive Officer	Bought 5 parts	814,606	$15.29 average	$12.5M	6.7%	Form 4
Feb 27 – Mar 3	Kevin Tang Director	Bought 6 parts	900,000	$14.10 average	$12.7M	7.9%	Form 4
Aug 1, 2025 – Aug 5, 2025	Kevin Tang Director	Bought 3 parts	1,300,000	$10.45 average	$13.6M	13%	Form 4
Aug 1, 2025	Greg Keenan Chief Medical Officer	SoldNo plan	20,000	$10.50	210K	13%	Form 4
Mar 7, 2025	Greg Keenan Chief Medical Officer	SoldNo plan	8,305	$8.23	68K	5.1%	Form 4
Mar 3, 2025 – Mar 4, 2025	Peter Greenleaf Chief Executive Officer	SoldNo plan 2 parts	360,540	$7.96 average	$2.87M	17%	Form 4
Mar 3, 2025 – Mar 4, 2025	Joseph M Miller Chief Financial Officer	SoldNo plan 2 parts	118,013	$7.96 average	940K	17%	Form 4
Mar 3, 2025 – Mar 4, 2025	Stephen P. Robertson EVP, General Counsel	SoldNo plan 2 parts	122,479	$7.96 average	975K	19%	Form 4
Mar 3, 2025 – Mar 4, 2025	Matthew Maxwell Donley Chief Operating Officer	SoldNo plan 2 parts	124,893	$7.96 average	994K	16%	Form 4
Feb 28, 2025 – Mar 4, 2025	Kevin Tang Director	Bought 6 parts	1,600,000	$7.95 average	$12.7M	19%	Form 4
Mar 3, 2025	Greg Keenan Chief Medical Officer	SoldNo plan	12,239	$8.00	98K	7.0%	Form 4
Dec 5, 2024 – Dec 9, 2024	Kevin Tang Director	Bought 3 parts	1,200,000	$9.02 average	$10.8M	17%	Form 4
Nov 11, 2024	Jeffrey Allen Bailey Director	SoldNo plan	4,557	$8.43	38K	25%	Form 4
Nov 11, 2024	Karen L. Smith Director	SoldNo plan	5,241	$8.43	44K	29%	Form 4

Sep 10No plan
Stephen P. Robertson
Chief Legal Officer · sold 11,939 at $15.95
190K
2.0% of stake
Aug 21No plan
Stephen P. Robertson
Chief Legal Officer · sold 20,975 at $16.97
356K
3.4% of stake
May 29 – Jun 2
Kevin Tang
Chief Executive Officer · bought 814,606 at avg $15.29
$12.5M
6.7% of stake
Feb 27 – Mar 3
Kevin Tang
Director · bought 900,000 at avg $14.10
$12.7M
7.9% of stake
Aug 1, 2025 – Aug 5, 2025
Kevin Tang
Director · bought 1,300,000 at avg $10.45
$13.6M
13% of stake
Aug 1, 2025No plan
Greg Keenan
Chief Medical Officer · sold 20,000 at $10.50
210K
13% of stake
Mar 7, 2025No plan
Greg Keenan
Chief Medical Officer · sold 8,305 at $8.23
68K
5.1% of stake
Mar 3, 2025 – Mar 4, 2025No plan
Peter Greenleaf
Chief Executive Officer · sold 360,540 at avg $7.96
$2.87M
17% of stake
Mar 3, 2025 – Mar 4, 2025No plan
Joseph M Miller
Chief Financial Officer · sold 118,013 at avg $7.96
940K
17% of stake
Mar 3, 2025 – Mar 4, 2025No plan
Stephen P. Robertson
EVP, General Counsel · sold 122,479 at avg $7.96
975K
19% of stake
Mar 3, 2025 – Mar 4, 2025No plan
Matthew Maxwell Donley
Chief Operating Officer · sold 124,893 at avg $7.96
994K
16% of stake
Feb 28, 2025 – Mar 4, 2025
Kevin Tang
Director · bought 1,600,000 at avg $7.95
$12.7M
19% of stake
Mar 3, 2025No plan
Greg Keenan
Chief Medical Officer · sold 12,239 at $8.00
98K
7.0% of stake
Dec 5, 2024 – Dec 9, 2024
Kevin Tang
Director · bought 1,200,000 at avg $9.02
$10.8M
17% of stake
Nov 11, 2024No plan
Jeffrey Allen Bailey
Director · sold 4,557 at $8.43
38K
25% of stake
Nov 11, 2024No plan
Karen L. Smith
Director · sold 5,241 at $8.43
44K
29% of stake

How to read this. Insiders sell for many reasons: taxes, diversifying, a house. Open-market buys are rarer and say more. A 10b5-1 plan is a trading schedule set up months in advance, so those sales were not timed on news. Large holders (funds and 10% owners) are listed under Everything but not counted as insiders. If you own or watch AUPH, we send a push when an executive buys or makes a large sale outside a plan.

Source: SEC Form 4 filings, filed within two business days of each trade and checked for new ones every hour.

Peers

Pharmaceutical Preparations · Pick stocks to compare with AUPH

CompareIntrinsic value

ARVNArvinas Inc.

$7.42+4.65%40

EOLSEvolus Inc.

$7.47+1.36%30

XERSXeris Biopharma Holdings, Inc.

$10.46+1.06%30

LGNDLigand Pharmaceuticals Inc.

$316.13+0.83%36

PTGXProtagonist Therapeutics Inc.

$143.37+2.23%54

RIGLRigel Pharmaceuticals, Inc.

$51.29+4.97%87

HROWHarrow Inc.

$28.75+0.74%46

PHATPhathom Pharmaceuticals Inc.

$5.68-1.05%10

Held by ETFs

AUPH is in 56 US ETFs. The largest of them, with AUPH's weight in each:

Spot a number that looks wrong? Check it in AUPH's SEC filings or

Download this analysis as a PDF (Pro)

Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.

2 of 2 free stocks used today

Keep analysing AUPH

Create a free account and get 14 days of Premium: every stock and every tool.

Unlimited stocksQuality, fair value and dividends for 10,000+ stocks
Stock screenerFilter on quality, valuation and dividend safety
Portfolio trackerReal return, dividend calendar and portfolio quality
Editable DCFChange the assumptions and watch fair value move
Compare side by sideUp to 10 stocks in one table
Unlimited alertsPrice, P/E, Quality Score and yield

No card. Moves to Free after, unless you upgrade.

Already have an account?

Or come back tomorrow. Stocks on your watchlist are always free to view.